Quick access to main page (top) Direct access to main contents Quick access to main page (bottom)

Bristol-Myers’ Schizophrenia Drug Falls Short in Key Trial

Daniel Kim Views  

Shutterstock
Shutterstock

Bristol-Myers Squibb (BMS) recently revealed that a late-stage clinical trial for the expanded use of its medication, Cobenfy, did not yield statistically significant results.

According to reports, the medication, which was approved last year, failed to meet its primary objective in this trial involving schizophrenia patients who did not improve with current antipsychotic therapies.

At week six of the trial, the medication demonstrated a 2 percentage point drop in a symptom severity measure compared to a placebo.

Bristol-Myers has completed the analysis of all trial data and intends to present the findings in depth at a future academic conference.

Daniel Kim
content@viewusglobal.com

Comments0

300

Comments0

[LIFESTYLE] Latest Stories

  • Experts Warn: Toss Your Expired Sunscreen Before It Hurts Your Skin
  • New Drug Helps Patients with Myasthenia Gravis Breathe and Speak Easier
  • Novavax COVID Vaccine Still on Hold—More Trials Needed, Says FDA
  • Want to Lower Your Blood Pressure? Eat More Bananas, Study Says
  • Weekend Workouts Are Enough to Cut Diabetes Risk, Study Says
  • Brushing Right After Eating Could Hurt Your Teeth—Here’s Why